EIC Accelerator

Vivalyx operates a patented organ preservation system designed to enhance the success of organ transplantation. Its technology combines static cold storage with machine perfusion, offering a blood-free alternative that aims to increase the vitality and availability of donor organs, thereby improving patient outcomes.

Vivalyx operates a patented organ preservation system designed to enhance the success of organ transplantation. Its technology combines static cold storage with machine perfusion, offering a blood-free alternative that aims to increase the vitality and availability of donor organs, thereby improving patient outcomes.

BioThrust develops customized gassing solutions for bioreactors.

BioThrust develops customized gassing solutions for bioreactors.

TreeFrog Therapeutics is a stem cell company focused on scalable production of stem cells for cell therapies. It develops and uses a proprietary end-to-end 3D bioreactor-based platform called C-Stem to enable scalable, cGMP-compliant manufacturing. Founded in 2018 and based in Pessac, France, the company aims to secure cell production and quality, accelerate clinical development, and improve market access by reducing treatment costs. The platform addresses manufacturing bottlenecks in the cell therapy sector, offering an integrated solution from cell culture to manufacturing readiness to support safe, affordable stem cell therapies.

MyoPax develops advanced regenerative therapies using stem cells to address debilitating muscle illnesses.

MyoPax develops advanced regenerative therapies using stem cells to address debilitating muscle illnesses.

Arctic Therapeutics is a drug discovery and development company that focuses on identifying the genetic underpinnings of major and rare diseases. It employs bioinformatics and artificial intelligence to mitigate risks and reduce costs and development timelines in traditional drug development, while its research and development is guided by a global team of experts in genetics, genomics, immunology, bioinformatics, and drug development.

BioSourcing is a biotechnology company based in Liège, Belgium, focused on developing a new generation of biotherapeutics, particularly monoclonal antibodies, to address global unmet medical needs. The company employs advanced technologies, including genome editing techniques like CRISPR, to innovate the design of biotherapeutics. This disruptive approach significantly reduces capital requirements and production costs, especially for large-scale manufacturing, while enhancing the quality and efficiency of biopharmaceuticals through improved glycosylation processes. BioSourcing is committed to sustainability, aiming to minimize the carbon footprint associated with biotherapeutic production. The company boasts a team of leading scientists and international experts, supported by strategic partnerships with key players in the pharmaceutical and biotechnology sectors.

BioSourcing is a biotechnology company based in Liège, Belgium, focused on developing a new generation of biotherapeutics, particularly monoclonal antibodies, to address global unmet medical needs. The company employs advanced technologies, including genome editing techniques like CRISPR, to innovate the design of biotherapeutics. This disruptive approach significantly reduces capital requirements and production costs, especially for large-scale manufacturing, while enhancing the quality and efficiency of biopharmaceuticals through improved glycosylation processes. BioSourcing is committed to sustainability, aiming to minimize the carbon footprint associated with biotherapeutic production. The company boasts a team of leading scientists and international experts, supported by strategic partnerships with key players in the pharmaceutical and biotechnology sectors.

Cherry Biotech is a biomedical technology company that develops Organ on Chip instruments and microfluidic systems to culture and mimic human organs under physio-pathological conditions for drug discovery and personalized medicine. The company also offers temperature controllers for rapid temperature shifts and next-generation 3D cell culture technologies to recreate the human cell microenvironment, supporting drug development and toxicity assessment.

Solmeyea is a biotechnology company specializing in producing single-cell proteins from CO2 at scale. These proteins serve as carbon-negative ingredients for various food applications. The company also explores producing biomaterials and commodities from CO2, aiming to contribute to CO2 circularity. Solmeyea collaborates with corporations emitting high levels of CO2, transforming their emissions into valuable products to address climate change and food insecurity.

Vaxdyn is a biotechnology company focused on the development of vaccines and immunotherapies aimed at preventing infectious diseases, particularly those caused by antibiotic-resistant pathogens. Utilizing innovative technology, Vaxdyn's vaccines incorporate antigens, immunomodulators, nanoparticles, and monoclonal antibodies to effectively combat bacterial infections. This approach helps healthcare professionals mitigate the public health impact of infections that are resistant to traditional treatments. The company actively engages with its customers through various communication channels, including phone, email, and online applications, to address inquiries related to their vaccine offerings.

Solmeyea is a biotechnology company specializing in producing single-cell proteins from CO2 at scale. These proteins serve as carbon-negative ingredients for various food applications. The company also explores producing biomaterials and commodities from CO2, aiming to contribute to CO2 circularity. Solmeyea collaborates with corporations emitting high levels of CO2, transforming their emissions into valuable products to address climate change and food insecurity.

Apmonia Therapeutics develops peptide-based therapies targeting the tumor microenvironment to improve cancer patient outcomes. Their focus includes glioblastoma, ovarian, colorectal, and pancreatic cancers.

Cherry Biotech is a biomedical technology company that develops Organ on Chip instruments and microfluidic systems to culture and mimic human organs under physio-pathological conditions for drug discovery and personalized medicine. The company also offers temperature controllers for rapid temperature shifts and next-generation 3D cell culture technologies to recreate the human cell microenvironment, supporting drug development and toxicity assessment.

SpacePharma SA is a Swiss company established in 2012, specializing in providing microgravity services and solutions for research. Based in Delémont, the company offers an innovative miniaturized laboratory system called mGnify, which can be remotely controlled and utilized across various microgravity platforms, including ground simulators, parabolic flights, and nano satellites. By facilitating access to microgravity environments, SpacePharma enables researchers to conduct advanced studies in areas such as bio-chemistry, drug screening, gene expression, protein crystallization, and the pathogenicity of bacteria. The company assists clients throughout all phases of their experiments, employing cutting-edge technology to deliver unique data and accelerate research and development processes.

Vaxdyn is a biotechnology company focused on the development of vaccines and immunotherapies aimed at preventing infectious diseases, particularly those caused by antibiotic-resistant pathogens. Utilizing innovative technology, Vaxdyn's vaccines incorporate antigens, immunomodulators, nanoparticles, and monoclonal antibodies to effectively combat bacterial infections. This approach helps healthcare professionals mitigate the public health impact of infections that are resistant to traditional treatments. The company actively engages with its customers through various communication channels, including phone, email, and online applications, to address inquiries related to their vaccine offerings.

SpacePharma SA is a Swiss company established in 2012, specializing in providing microgravity services and solutions for research. Based in Delémont, the company offers an innovative miniaturized laboratory system called mGnify, which can be remotely controlled and utilized across various microgravity platforms, including ground simulators, parabolic flights, and nano satellites. By facilitating access to microgravity environments, SpacePharma enables researchers to conduct advanced studies in areas such as bio-chemistry, drug screening, gene expression, protein crystallization, and the pathogenicity of bacteria. The company assists clients throughout all phases of their experiments, employing cutting-edge technology to deliver unique data and accelerate research and development processes.

JaxBio develops AI-driven diagnostic technology for cancer, using AI-based chips for genetic and epigenetic profiling and array-based cancer tests to enable a simple, sensitive blood test for cancer detection and monitoring. Its technology identifies biomarker sets that distinguish cancer types and subtypes across stages, supporting early detection, disease monitoring, and prediction of treatment response.

BestHealth4U specializes in developing advanced adhesive technologies for medical applications. Their innovative solutions aim to prevent skin injuries, enhance healing, and improve overall patient health by transforming how bandages, dressings, and medical devices adhere to the skin.

SpacePharma SA is a Swiss company established in 2012, specializing in providing microgravity services and solutions for research. Based in Delémont, the company offers an innovative miniaturized laboratory system called mGnify, which can be remotely controlled and utilized across various microgravity platforms, including ground simulators, parabolic flights, and nano satellites. By facilitating access to microgravity environments, SpacePharma enables researchers to conduct advanced studies in areas such as bio-chemistry, drug screening, gene expression, protein crystallization, and the pathogenicity of bacteria. The company assists clients throughout all phases of their experiments, employing cutting-edge technology to deliver unique data and accelerate research and development processes.

TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, specializing in the development of genetically modified oncolytic viruses to enhance T-cell therapies for cancer treatment. Established in 2013, the company focuses on utilizing its patented technology to improve tumor-infiltrating lymphocyte (TIL) and chimeric antigen receptor (CAR-T) therapies, as well as checkpoint inhibiting antibody treatments. TILT Biotherapeutics is advancing products such as TILT-123, TILT-234, and TILT-321, which aim to modify the tumor microenvironment and boost immune responses against cancer. The company's innovative approach holds promise for achieving effective results in treating solid tumors, paralleling the successes seen in hematological tumors.

Apmonia Therapeutics develops peptide-based therapies targeting the tumor microenvironment to improve cancer patient outcomes. Their focus includes glioblastoma, ovarian, colorectal, and pancreatic cancers.

BestHealth4U specializes in developing advanced adhesive technologies for medical applications. Their innovative solutions aim to prevent skin injuries, enhance healing, and improve overall patient health by transforming how bandages, dressings, and medical devices adhere to the skin.

SpacePharma SA is a Swiss company established in 2012, specializing in providing microgravity services and solutions for research. Based in Delémont, the company offers an innovative miniaturized laboratory system called mGnify, which can be remotely controlled and utilized across various microgravity platforms, including ground simulators, parabolic flights, and nano satellites. By facilitating access to microgravity environments, SpacePharma enables researchers to conduct advanced studies in areas such as bio-chemistry, drug screening, gene expression, protein crystallization, and the pathogenicity of bacteria. The company assists clients throughout all phases of their experiments, employing cutting-edge technology to deliver unique data and accelerate research and development processes.

Iris.ai offers an AI-powered science assistant designed for R&D departments. It enhances research efficiency through smart search, filters, summaries, and autonomous extraction of scientific insights.

Scope Biosciences develops molecular diagnostics leveraging CRISPR-Cas technology. It originated as a spin-off from Wageningen University & Research. The company aims to provide actionable nucleic acid detection in healthcare and agriculture with high specificity for single-nucleotide differences and sensitivity to trace genetic material, packaged in a format that can be used outside traditional laboratory settings to support on-site decision making by clinicians and agricultural professionals.

Qlucore is a prominent provider of advanced bioinformatics software designed for research and precision diagnostics in the life sciences. Founded in 2007 by researchers from Lund University in Sweden, the company aims to simplify the analysis of complex data generated in the fields of genetics and proteomics. Its flagship product, Qlucore Omics Explorer, is a user-friendly bioinformatics tool that enables researchers, technicians, and physicians to easily interpret and visualize large datasets. Additionally, Qlucore offers Qlucore Diagnostics, an AI-powered platform for multi-omics companion and precision diagnostics that integrates with various data-generating instruments. With a global presence, Qlucore serves customers in approximately 35 countries, including leading pharmaceutical companies, hospitals, and academic institutions.

HAWK Biosystems develops a companion diagnostics platform designed to quantify protein-protein interactions and their post-translational modifications in single-cell and fixed tissue samples. This platform offers built-in specificity while preserving the morphological integrity and cellular heterogeneity of tissues, enabling more precise treatment decisions in cancer, inflammation, and immune disorders.

KLISBio is a pioneering company in regenerative medicine that utilizes silk as a versatile and biocompatible scaffold material to advance tissue regeneration methods. The company focuses on various clinical applications within the orthopedic and vascular markets, developing innovative silk-based biomaterials that facilitate the regeneration of human tissues. These materials are designed to degrade safely within the body, making them suitable for medical research and treatment of tissue-related diseases. By harnessing the potential of nano-fibers, KLISBio aims to transform the landscape of medical technology and improve patient outcomes.

Hoba Therapeutics is focused on developing innovative biopharmaceuticals aimed at treating neuropathic pain and central nervous system disorders. The company is advancing a novel therapeutic protein designed to target specific cells, providing medical practitioners with effective and safe options for managing chronic pain and hearing loss. Through its research and development efforts, Hoba Therapeutics seeks to deliver disease-modifying treatments that enhance the quality of life for patients suffering from neuropathic pain.

Genewity B.V. is a biotech company that works closely with LUmc to build on the achievements of our scientific and business teams in cell and gene therapies.

Hooke Bio Ltd. is a biotechnology company based in Shannon, Ireland, focused on developing microfluidic technologies for drug screening and related applications. Founded in 2014, the company has created a fully integrated high-throughput screening system that utilizes 3D microtissues, such as spheroids and organoids, to generate biological data. This innovative, patent-protected technology aims to reduce reliance on animal models in preclinical studies and accelerate the drug development process. By enabling pharmaceutical companies and clinicians to develop more accurate disease models and optimize treatments based on individual patient samples, Hooke Bio enhances the ability to test and repurpose drugs effectively, ultimately improving patient care and outcomes.

BioSimulytics is a company that specializes in creating AI-powered software tailored for drug researchers in the pharmaceutical industry. Its innovative platform integrates molecular chemistry, quantum physics, and advanced artificial intelligence to enhance the drug development process. By focusing on crystal-structure prediction, BioSimulytics enables researchers to accurately predict stable polymorphs, which significantly improves the speed, certainty, and quality of product data. This technology aims to streamline the development of pharmaceuticals, ultimately supporting researchers in their quest to bring new drugs to market more efficiently.

Hemispherian is a biotechnology firm focused on developing innovative treatments for various types of cancer, particularly aggressive forms such as glioblastoma multiforme. The company specializes in creating personalized cancer therapies and is engaged in the development of a novel class of small-molecule drugs. By concentrating on areas of unmet medical need, Hemispherian aims to provide physicians with access to advanced therapeutic options that could improve patient outcomes in challenging cancer cases.

Hemispherian is a biotechnology firm focused on developing innovative treatments for various types of cancer, particularly aggressive forms such as glioblastoma multiforme. The company specializes in creating personalized cancer therapies and is engaged in the development of a novel class of small-molecule drugs. By concentrating on areas of unmet medical need, Hemispherian aims to provide physicians with access to advanced therapeutic options that could improve patient outcomes in challenging cancer cases.

ReST Therapeutics is a clinical biotechnology company focused on developing innovative therapies for complex central nervous system (CNS) disorders. Utilizing its patented medication candidate, the company aims to create treatments that selectively target NMDA receptors, with the intention of addressing conditions such as post-traumatic stress disorder (PTSD) and Alzheimer's disease. By advancing its candidate through non-clinical testing, ReST Therapeutics seeks to improve the efficacy of cognitive preservation and provide protection against neurotoxicity, thereby enhancing therapeutic outcomes for patients suffering from these debilitating neural disorders.

ResoTher Pharma is a privately held biotechnology company based in Copenhagen, Denmark. The company specializes in developing peptide-based drugs derived from Annexin A1, an endogenous immunomodulator. These drugs are designed as resolution therapies for diseases where neutrophil-driven inflammation is a key pathological factor. ResoTher Pharma's primary focus is on addressing cardiovascular and inflammatory disorders that have significant unmet medical needs. Their patented peptide drugs target a G-protein coupled receptor expressed on leukocytes, aiming to mimic the body's natural response to resolving inflammation and promoting tissue repair.